Correction of Potentially Modified Risk Factors in Hemodialysis Treatment: Standards of Therapy and Individualized Programs of Dialysis
Journal Title: Нирки - Year 2015, Vol 3, Issue 13
Abstract
Limitations of possible correction for potentially modified factor the risk of death of patients, who are on renal replacement therapy, by techniques of hemodialysis were studied. The conclusions about the possibility of modern dialysis methods to effectively influence arterial hypertension in patients with chronic kidney disease stage 5D and the need of their further study in order to develop treatment standards with the use of mathematical models of individual dialysis programs were made.
Authors and Affiliations
I. L. Kuchma
Keywords
Related Articles
- EP ID EP215094
- DOI -
- Views 100
- Downloads 0
Resistance of bacteria isolated in urinary tract infections to antimicrobial drugs in children
Background. Urinary tract infection (UTI) is one of the main causes of hospitalization of children. One of the main causes of ineffective treatment of UTI in children is the antibiotic resistance of UTI pathogens. The pu...
Next Step in Chronic Kidney Disease Therapy
Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers are the basis of renoprotection therapy in chronic kidney disease. Parallel to decrease of glomerular filtration rate, there is an increase in the ac...
Evaluating the Effectiveness of the Treatment for Inflammatory Disorders of Male Genital Organs of Trichomonal Bacterial Origin Using Grandazol
The article presents the results of studying clinical and microbiological efficacy of Grandazol in the comprehensive treatment for inflammatory disorders of male genital organs of trichomonal bacterial origin.
Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice
Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney dis...
Active Follow-up in Patients with Localized Prostate Cancer: Evaluation of Long-term Results
Among the clinical recommendations one of the standard approaches in the treatment of prostate cancer is active follow-up. For 13 years, under the supervision there were 85.7 % of patients. Overall 3-, 5- and 7-year surv...